Antag Therapeutics ApS, a Denmark-based privately-held biotechnology company, announced on Thursday that it has named Dr Christine Fischette as its new director.

Dr Fischette has more than 30 years of pharmaceutical experience. She has held strategic and operational roles within research, drug development, commercialisation and business development at Hoffman-LaRoche, Pfizer and Novartis. She has worked on multiple private company Business/Scientific Advisory Boards for therapeutics and devices. She has served as executive director/senior advisor at the boutique biopharma investment banks Torreya Partners and Griffin Securities.

Dr Fischette has a BA in Biology Education from Rutgers University and a PhD in Physiology from Rutgers Biomedical Health Sciences, formerly known as the University of Medicine and Dentistry of New Jersey.